Welcome to our dedicated page for VVY news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Summary not available.
Summary not available.
Summary not available.
Vivoryon Therapeutics N.V. announces participation in two key investor conferences:
- Van Lanschot Kempen Life Sciences Conference on April 25-26, 2023, featuring one-on-one meetings in Amsterdam.
- Bio€quity Europe on May 14-16, 2023, with a presentation scheduled for May 16, 2023, at 10:44 am IST in Dublin.
As a clinical-stage biotechnology company, Vivoryon focuses on developing small molecule medicines aimed at modulating pathologically altered proteins, including its lead program, varoglutamstat, which targets Alzheimer’s disease in Phase 2 clinical development. The company is committed to advancing treatments for severe diseases, utilizing extensive expertise in protein modifications.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) reported its full-year 2022 financial results, highlighting advancements in clinical trials for varoglutamstat, a potential treatment for Alzheimer’s disease. The VIVIAD and VIVA-MIND studies progressed significantly, with final data from VIVIAD expected in Q1 2024 and a clinical update on VIVA-MIND anticipated in 2H 2023. The company bolstered its financial position with two successful private placements totaling EUR 36 million, with an option for up to an additional EUR 15 million. Despite a net loss of EUR 28.2 million in 2022, an increase from EUR 12.7 million in 2021, the cash balance at year-end stood at EUR 26.6 million, supporting operations through at least December 2023. Management is optimistic about ongoing trials and the potential for future partnerships.
Vivoryon Therapeutics N.V. will report its full year 2022 financial results and operational progress on April 19, 2023. The conference call is scheduled for 03:00 pm CEST / 09:00 am EDT and will be available via phone and webcast. The report will be accessible on their website. Vivoryon is dedicated to developing small molecule medicines aimed at modulating altered proteins in various diseases, including a lead program in Phase 2 clinical trials for Alzheimer’s disease. The company is also advancing a solid pipeline of molecules targeting other conditions such as cancer and fibrosis.
Vivoryon Therapeutics N.V. recently provided an update on its clinical development of varoglutamstat, targeting Alzheimer's disease (AD). The VIVIAD Phase 2b study in Europe is set for final data in Q1 2024, demonstrating positive safety results in over 100 patients with no on-target toxicity or ARIA signs. In the U.S., the VIVA-MIND Phase 2 study is progressing with 18 sites actively enrolling patients. Both studies indicate low discontinuation rates and effective recruitment strategies. Varoglutamstat's design aims to address key AD challenges, enhancing patient treatment adherence and targeting neurotoxic pathways.
Vivoryon Therapeutics N.V. announced that CEO Dr. Ulrich Dauer will present at significant investor conferences in March 2023. The events include the BioCapital Europe 2023 on March 9, the Barclays Global Healthcare Conference on March 16, and the German Biotechnology Days on March 29. A webcast of these presentations will be accessible on their website.
Vivoryon Therapeutics N.V. announced that Dr. Ulrich Dauer, the CEO, will present at the 2023 BIO CEO & Investor Conference in New York City on February 6 at 10:15 am EST. The conference, scheduled from February 6-9, 2023, will feature insights into the company’s innovative approach to treating Alzheimer’s disease through its oral small molecule QPCT/L inhibitor, varoglutamstat, currently in Phase 2 development. Vivoryon focuses on developing small molecule medicines targeting altered proteins in various diseases, including cancer and inflammatory conditions. The presentation is for registered attendees only.